Dr. Reddy's Lab. voluntarily recalls all Ranitidine medicines from US market
Dr Reddy's Laboratories on Wednesday said that it has voluntarily recalled all its Ranitidine medicines from US market due to contamination with probable cancer causing N-Nitrosodimethylamine (NDMA).
The recall started on October 1st after the United States Food and Drugs Administration (USFDA) found the presence of NDMA in certain Ranitidine medicines above permissible level. The recall has been initiated at retail level for Over-the-counter products and at consumer level for prescription products on all of Ranitidine medications sold in US market.
Dr Reddy's Laboratories Limited is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses namely Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products, Dr Reddy's offers various products and services including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations. The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
On Wednesday, the stock of Dr. Reddy's Laboratories Ltd. opened at Rs. 2817.90 per share and made an intraday high and low of Rs. 2839.95 and Rs. 2756.10, respectively on the BESE. The stock closed at Rs. 2826.70, up by 0.51 per cent.